1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. Company
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cellectis S.A.
Cellectis S.A. is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis S.A. is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis S.A. remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Number of employees : 294 people.
Sales per Business
20202021Delta
Therapeutics44.7969%25.6753% -42.67%
Plants20.0831%22.8047% +13.53%
EUR in Million
Sales per region
20202021Delta
France44.7969%25.6753% -42.67%
United States20.0831%22.8047% +13.53%
EUR in Million
Managers
Name Title Age Since
André Choulika, Dr. Chief Executive Officer & Director 56 2020
Bing C. Wang, Dr. Chief Financial Officer - 2022
Philippe Duchateau, Dr. Chief Scientific Officer 58 2012
Carrie Brownstein Chief Medical Officer 51 2020
Stephan Reynier Chief Regulatory & Compliance Officer 52 2011
Arthur Stril Chief Business Officer - 2020
Marie-Bleuenn Terrier Secretary & General Counsel 39 2015
David J. Sourdive, Dr. Director & Executive VP-CMC & Manufacturing 54 -
Steve Doares, Dr. Senior Vice President-US Manufacturing - 2020
Kyung Nam-Wortman Chief Human Resources Officer & Executive VP - 2020
Members of the board
Name Title Age Since
Jean-Pierre Garnier Non-Executive Chairman 73 2020
Alain Godard Independent Director 75 2007
Laurent Arthaud Independent Director 59 -
Pierre Bastid Independent Director 67 2011
Annick Schwebig, Dr. Independent Director 71 2011
Hervé Hoppenot Independent Director 61 2017
Rainer Boehm, Dr. Independent Director 60 2017
David J. Sourdive, Dr. Director & Executive VP-CMC & Manufacturing 54 -
André Choulika, Dr. Chief Executive Officer & Director 56 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 45,484,310 38,352,927 84.3% 0 0.0% 84.3%
Shareholders
NameEquities%
Bpifrance Participations SA /PRIVATE EQUITY/ 3,686,287 8.11%
Baillie Gifford & Co. 3,256,372 7.16%
Pierre Bastid 1,862,016 4.09%
Capital Research & Management Co. (World Investors) 1,079,240 2.37%
André Choulika 996,033 2.19%
David J. Sourdive 983,035 2.16%
Capital Research & Management Co. (International Investors) 581,748 1.28%
Norges Bank Investment Management 518,999 1.14%
BlackRock Fund Advisors 429,434 0.94%
Bessemer Investment Management LLC 389,059 0.86%
Holdings
NameEquities%Valuation
CALYXT, INC. (CLXT) 23,963,175 56.0% 10,543,797 USD
Markets and indexes
- PEA / SRD eligible : YES / NO
- Euronext Growth Paris
- Euronext Growth All-Share / CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- Bloomberg Code :  ALCLS:FP
- Reuters Code :  ALCLS.PA
- Datastream Code :  
Company contact information
Cellectis S.A.
8 Rue de la Croix-Jarry
FR-75013 Paris

Phone : +33 (0)1 81 69 16 00
Fax : +33 (0)1 81 69 16 06
web site : https://www.cellectis.com/fr/investisseur/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Cellectis S.A.